1. Home
  2. DAWN vs PRTH Comparison

DAWN vs PRTH Comparison

Compare DAWN & PRTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • PRTH
  • Stock Information
  • Founded
  • DAWN 2018
  • PRTH 2005
  • Country
  • DAWN United States
  • PRTH United States
  • Employees
  • DAWN N/A
  • PRTH N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • PRTH EDP Services
  • Sector
  • DAWN Health Care
  • PRTH Technology
  • Exchange
  • DAWN Nasdaq
  • PRTH Nasdaq
  • Market Cap
  • DAWN 624.8M
  • PRTH 545.8M
  • IPO Year
  • DAWN 2021
  • PRTH N/A
  • Fundamental
  • Price
  • DAWN $7.47
  • PRTH $6.77
  • Analyst Decision
  • DAWN Strong Buy
  • PRTH Strong Buy
  • Analyst Count
  • DAWN 7
  • PRTH 4
  • Target Price
  • DAWN $27.86
  • PRTH $12.25
  • AVG Volume (30 Days)
  • DAWN 1.5M
  • PRTH 479.2K
  • Earning Date
  • DAWN 10-30-2025
  • PRTH 11-06-2025
  • Dividend Yield
  • DAWN N/A
  • PRTH N/A
  • EPS Growth
  • DAWN N/A
  • PRTH N/A
  • EPS
  • DAWN N/A
  • PRTH 0.26
  • Revenue
  • DAWN $187,638,000.00
  • PRTH $918,558,000.00
  • Revenue This Year
  • DAWN $12.96
  • PRTH $13.01
  • Revenue Next Year
  • DAWN $48.40
  • PRTH $10.85
  • P/E Ratio
  • DAWN N/A
  • PRTH $25.68
  • Revenue Growth
  • DAWN 2190.50
  • PRTH 12.86
  • 52 Week Low
  • DAWN $5.64
  • PRTH $5.01
  • 52 Week High
  • DAWN $16.76
  • PRTH $12.47
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 53.82
  • PRTH 38.70
  • Support Level
  • DAWN $6.99
  • PRTH $7.00
  • Resistance Level
  • DAWN $7.73
  • PRTH $7.56
  • Average True Range (ATR)
  • DAWN 0.44
  • PRTH 0.34
  • MACD
  • DAWN 0.02
  • PRTH 0.01
  • Stochastic Oscillator
  • DAWN 48.73
  • PRTH 7.38

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

About PRTH Priority Technology Holdings Inc.

Priority Technology Holdings Inc is a provider of merchant acquiring and commercial payment solutions to small and medium business enterprises in the United States. The company has three reportable segments which are SMB Payments, B2B Payments, and Enterprise Payments. SMB Payments segment which generates the majority of revenue provides full-service acquiring and payment-enabled solutions for B2C transactions, leveraging Priority's proprietary software platform, distributed through ISO; the B2B Payments segment provides AP automation solutions to corporations, software partners, & industry FIs: and Enterprise Payments segment provides embedded payment & treasury solutions to enterprise customers to modernize legacy platforms & accelerate software partners' strategies to monetize payments.

Share on Social Networks: